wet AMD

Read more about the article EyeWorld Weekly, January 9, 2026
EyeWorld Weekly

EyeWorld Weekly, January 9, 2026

➤ FDA accepts BLA for thyroid eye treatment ➤ Breakthrough Therapy Designation granted to investigational neuroprotective for optic neuropathies ➤ FDA issues complete response letter for wet AMD BLA resubmission ➤ Biosimilar approved for retinal therapies ➤ FDA approves IND for corneal genome editing program ➤ Study: ‘largest prospective trial ever’ on postcataract endophthalmitis prophylaxis ➤ Complimentary access to video journal ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, January 9, 2026
January 9, 2026
Read more about the article EyeWorld Weekly, May 30, 2025
EyeWorld Weekly

EyeWorld Weekly, May 30, 2025

➤ Phase 2 results for autoimmune-related dry eye disease immunomodulator ➤ JCRS astigmatism working group publishes two papers ➤ FDA approves therapy for diabetic retinopathy ➤ Enrollment closes for largest retinal trial of its kind to date ➤ Enrollment complete for Phase 3 trial evaluating wet AMD treatment ➤ Rare Pediatric Disease Designation granted for treatment targeting several retinopathies ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, May 30, 2025
May 30, 2025
Read more about the article EyeWorld Weekly, August 4, 2023
EyeWorld Weekly

EyeWorld Weekly, August 4, 2023

➤ Update on safety review of geographic atrophy drug ➤ IND application accepted by FDA for wet AMD gene therapy ➤ Phase 2 trial planned for investigational neuropathic corneal pain treatment ➤ Interim Phase 2 data for sustained wet AMD treatment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, August 4, 2023
August 4, 2023